clinical trial · NCT07400029
A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaObecabtagene Autoleucel
brief summary
The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual disease (MRD-negative, meaning there are no detectable cancer cells). Participants in this study will have received past treatment for their B-cell ALL, and their disease will be in MRD-negative CR for the first time (first MRD-negative CR).
started
Feb 3, 2026
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
Mar 24, 2026
official title
A Phase II Trial of Obecabtagene Autoleucel Consolidation in Adult Patients With Acute Lymphoblastic Leukemia in First Complete Remission Without Measurable Residual Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol